Allelic Loss of 10q23.3, the PTEN Gene Locus in Cervical Carcinoma from Northern Indian Population

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2011 Sep 9

PMID 21901275

Citations 12

Authors

M Moshahid Alam Rizvi

M Shabbir Alam

Syed Jafar Mehdi

Asgar Ali

Swaraj Batra

Affiliations

Soon will be listed here.

Abstract

Cervical cancer is one of the most common malignant diseases affecting women worldwide. Studies on loss of heterozygosity have been made for PTEN gene specific microsatellite markers in malignancies like breast, ovary and lungs and the results have shown a significant association. However the role of this gene is not clearly understood in cervical cancer from Indian population. A total of 135 cervical carcinoma tissues samples were analyzed for loss of heterozygosity. DNA was isolated from the samples and their matched control specimens. Polymerase chain reaction was performed using primer specific for two intragenic markers (D10S198 & D10S192) and one marker (D10S541) in flanking region and further electrophoresed on 8% denaturing polyacrylamide gel. Overall, 31 out of 133(23%) informative cases showed loss of heterozygosity in at least one locus in the region examined. The percentage of loss of heterozygosity for these markers ranged from 8% (D10S192) to 13% (D10S198). Loss of heterozygosity was more frequently detected in intragenic region (D10S198 & D10S192) than in flanking region, D10S541 (21% versus 9%). These data argue that PTEN is a tumor suppressor gene whose inactivation may play an important role in the carcinoma of uterine cervix.

Citing Articles

MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma.

Otoukesh B, Abbasi M, Gorgani H, Farahini H, Moghtadaei M, Boddouhi B Cancer Cell Int. 2020; 20:254.

PMID: 32565738 PMC: 7302353. DOI: 10.1186/s12935-020-01342-4.

PTEN and Gynecological Cancers.

Nero C, Ciccarone F, Pietragalla A, Scambia G Cancers (Basel). 2019; 11(10).

PMID: 31569439 PMC: 6826459. DOI: 10.3390/cancers11101458.

PTEN Genetic and Epigenetic Alterations Define Distinct Subgroups in North Indian Breast Cancer Patients.

Kazim Z, Wahabi K, Perwez A, Lal P, Rizvi M Asian Pac J Cancer Prev. 2019; 20(1):269-276.

PMID: 30678449 PMC: 6485588. DOI: 10.31557/APJCP.2019.20.1.269.

The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications.

Hu Z, Ma D Cancer Med. 2018; 7(10):5217-5236.

PMID: 30589505 PMC: 6198240. DOI: 10.1002/cam4.1501.

Inhibition of miRNA-21 attenuates the proliferation and metastasis of human osteosarcoma by upregulating PTEN.

Li C, Xu B, Miu X, Deng Z, Liao H, Hao L Exp Ther Med. 2018; 15(1):1036-1040.

PMID: 29434694 PMC: 5772948. DOI: 10.3892/etm.2017.5477.

References

Matsuyama H, Pan Y, Yoshihiro S, Kudren D, Naito K, Bergerheim U . Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate. 2002; 54(2):103-11. DOI: 10.1002/pros.10173. View

Lin J, Scherer S, Tougas L, Traverso G, Tsui L, Andrulis I . Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET. Oncogene. 1996; 13(9):2001-8. View

Hansen M, Cavenee W . Genetics of cancer predisposition. Cancer Res. 1987; 47(21):5518-27. View

Wishart M, Dixon J . PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol. 2002; 12(12):579-85. DOI: 10.1016/s0962-8924(02)02412-1. View

Steck P, Lin H, Langford L, Jasser S, Koul D, Yung W . Functional and molecular analyses of 10q deletions in human gliomas. Genes Chromosomes Cancer. 1999; 24(2):135-43. DOI: 10.1002/(sici)1098-2264(199902)24:2<135::aid-gcc6>3.0.co;2-a. View

Sankaranarayanan R, Budukh A, Rajkumar R . Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ. 2001; 79(10):954-62. PMC: 2566667. View

Konopka B, Janiec-Jankowska A, Paszko Z, Goluda M . The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma. J Cancer Res Clin Oncol. 2003; 130(2):114-21. DOI: 10.1007/s00432-003-0518-7. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Reid A, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D . Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer. 2010; 102(4):678-84. PMC: 2837564. DOI: 10.1038/sj.bjc.6605554. View

10.

Knudson A . Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993; 90(23):10914-21. PMC: 47892. DOI: 10.1073/pnas.90.23.10914. View

11.

Izycka-Swieszewska E, Brzeskwiniewicz M, Wozniak A, Drozynska E, Grajkowska W, Perek D . EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours. Folia Neuropathol. 2011; 48(4):238-45. View

12.

Benedet J, Bender H, Jones 3rd H, Ngan H, Pecorelli S . FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000; 70(2):209-62. View

13.

Stambolic V, Suzuki A, de la Pompa J, Brothers G, Mirtsos C, Sasaki T . Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 95(1):29-39. DOI: 10.1016/s0092-8674(00)81780-8. View

14.

Miyai K, Furugen Y, Matsumoto T, Iwabuchi K, Hirose S, Kinoshita K . Loss of heterozygosity analysis in uterine cervical adenocarcinoma. Gynecol Oncol. 2004; 94(1):115-20. DOI: 10.1016/j.ygyno.2004.04.013. View

15.

Xiao Y, Mao L, Han C, Li J, Xu L, Xin Y . MSI/LOH and extron expression of the FHIT gene in gastric carcinoma. Front Med China. 2014; 1(1):99-103. DOI: 10.1007/s11684-007-0019-1. View

16.

Orchiston E, Bennett D, Leslie N, Clarke R, Winward L, Downes C . PTEN M-CBR3, a versatile and selective regulator of inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P5). Evidence for Ins(1,3,4,5,6)P5 as a proliferative signal. J Biol Chem. 2003; 279(2):1116-22. DOI: 10.1074/jbc.M310933200. View

17.

Cho S, Lee C, Ahn Y, Kim H, Kim H, Ahn C . Redox regulation of PTEN and protein tyrosine phosphatases in H(2)O(2) mediated cell signaling. FEBS Lett. 2004; 560(1-3):7-13. DOI: 10.1016/s0014-5793(04)00112-7. View

18.

Siebert R, Gesk S, Harder S, Plotz S, Matthiesen P, Grote W . Deletions in the long arm of chromosome 10 in lymphomas with t(14;18): a pathogenetic role of the tumor supressor genes PTEN/MMAC1 and MXI1?. Blood. 1999; 92(11):4487-9. View

19.

Kurose K, Zhou X, Araki T, Eng C . Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas. Genes Chromosomes Cancer. 2000; 29(2):166-72. View

20.

Li Y, Tian Z, Wu D, Fu B, Xin Y . Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J Gastroenterol. 2005; 11(2):285-8. PMC: 4205419. DOI: 10.3748/wjg.v11.i2.285. View